At PL Neuro, we wanted one place to follow how neurotechnology was progressing: what researchers could measure and build, which companies were reaching clinical and commercial milestones, and where capital was going. We couldn’t quite find the combination we were looking for, so we built it ourselves.
Today, we’re launching Neuro Atlas, an interactive resource that brings those perspectives together.
The Milestone timeline follows developments across companies and over time. For example, you can trace Neuralink’s first human implantation in January 2024, Motif Neurotech’s FDA authorization to begin an early feasibility study for treatment-resistant depression in 2026, and Science’s CE mark for its PRIMA retinal implant in July 2026. It gives those individual announcements a place in the context of the field’s broader development.
Field Velocity looks at how technical capabilities are changing. Among other things, its charts track how many neurons can be recorded simultaneously, the size of published connectomes (think: wiring diagrams measured in neurons and synapses) and communication rates through brain-computer interfaces (BCIs). The underlying studies and methods help readers examine what the measurement means, how they are derived and who the researchers are that are contributing to the science. We will keep updating this as new papers and studies are published.
The BCI Funding Index adds the financing picture, bringing together funding rounds and investor participation. It includes for example Neuralink’s $650 million Series E in 2025, Tether’s $200 million investment in Blackrock Neurotech in 2024, and Science’s $400 million Series D in November 2026. Readers can explore how financing activity is developing alongside technical and clinical progress.
For a wider view of the companies working in neurotechnology, the Ecosystem section links directly to Neurofounders’ independently maintained startup map. There, you can discover companies such as 3Brain, which makes laboratory tools for recording electrical activity from brain cells; Aleva Neurotherapeutics, which develops directional deep-brain-stimulation technology; and Altoida, which develops investigational digital cognitive-assessment tools.
We hope Neuro Atlas will be useful to researchers and students putting new results in context, founders and technical teams following related work, and funders deciding where to investigate further. Writers and curious readers should also find it a useful starting point for understanding the field and digging deeper into the relevant material.
This is the kind of field building we’re proud to do at PL Neuro: turning scattered evidence into a useful public resource that researchers, builders, and funders can work from – and we hope to work with the community to improve it together.
We’d love your feedback and contributions. If you spot a missing paper or dataset, a company or financing milestone we should include, or a chart or method that could be improved, use the site’s Feedback button and send a primary-source link with your suggestion. Explore Neuro Atlas, share a chart, and tell us which questions you’d like it to help answer.